Soluble phospho‑tau from Alzheimer’s disease hippocampus drives microglial degeneration

The role of microglial cells in the development and progression of Alzheimer’s disease (AD) has not been elucidated. Here, we demonstrated the existence of a weak microglial response in human AD hippocampus which is in contrast to the massive microglial activation observed in APP-based models. Most...

Descripción completa

Detalles Bibliográficos
Autores: Sánchez Mejías, Elisabeth, Navarro Garrido, Victoria, Jiménez Muñoz, Sebastián, Sánchez Mico, María, Sánchez Varo, Raquel María, Núñez Díaz, Cristina, Trujillo Estrada, Laura Isabel, Dávila, José Carlos, Vizuete Chacón, María Luisa, Gutiérrez, Antonia, Vitorica Ferrández, Francisco Javier
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2016
País:España
Institución:Universidad de Sevilla (US)
Repositorio:idUS. Depósito de Investigación de la Universidad de Sevilla
OAI Identifier:oai:idus.us.es:11441/98796
Acceso en línea:https://hdl.handle.net/11441/98796
https://doi.org/10.1007/s00401-016-1630-5
Access Level:acceso abierto
Palabra clave:ALZHEIMER
MICROGLIA
PATHOLOGY
HUMAN BRAIN
HIPPOCAMPUS
Descripción
Sumario:The role of microglial cells in the development and progression of Alzheimer’s disease (AD) has not been elucidated. Here, we demonstrated the existence of a weak microglial response in human AD hippocampus which is in contrast to the massive microglial activation observed in APP-based models. Most importantly, microglial cells displayed a prominent degenerative profile (dentate gyrus > CA3 > CA1 > parahippocampal gyrus), including fragmented and dystrophic processes with spheroids, a reduced numerical density, and a significant decrease in the area of surveillance (“microglial domain”). Consequently, there was a substantial decline in the area covered by microglia which may compromise immune protection and, therefore, neuronal survival. In vitro experiments demonstrated that soluble fractions (extracellular/cytosolic) from AD hippocampi were toxic for microglial cells. This toxicity was abolished by AT8 and/or AT100 immunodepletion, validating that soluble phospho-tau was the toxic agent. These results were reproduced using soluble fractions from phospho-tau-positive Thy-tau22 hippocampi. Cultured microglial cells were not viable following phagocytosis of SH-SY5Y cells expressing soluble intracellular phospho-tau. Because the phagocytic capacity of microglial cells is highly induced by apoptotic signals in the affected neurons, we postulate that accumulation of intraneuronal soluble phospho-tau might trigger microglial degeneration in the AD hippocampus. This microglial vulnerability in AD pathology provides new insights into the immunological mechanisms underlying the disease progression and highlights the need to improve or develop new animal models, as the current models do not mimic the microglial pathology observed in the hippocampus of AD patients.